Download PDF
J Pediatr Infect Dis 2019; 14(03): 136-139
DOI: 10.1055/s-0037-1606330
Case Report
Georg Thieme Verlag KG Stuttgart · New York

Serial Microbiota Analysis after Fecal Microbiota Transplantation in a Child with Down's Syndrome

Yvette H. van Beurden
1   Department of Gastroenterology and Hepatology, VU University Medical Center, Amsterdam, The Netherlands
2   Department of Medical Microbiology and Infection Control, VU University Medical Center, Amsterdam, The Netherlands
,
Lisethe Meijer
3   Department of Pediatrics, University Medical Center Groningen, Groningen, The Netherlands
,
Clementien L. Vermont
3   Department of Pediatrics, University Medical Center Groningen, Groningen, The Netherlands
,
Andries E. Budding
2   Department of Medical Microbiology and Infection Control, VU University Medical Center, Amsterdam, The Netherlands
,
Chris J.J. Mulder
1   Department of Gastroenterology and Hepatology, VU University Medical Center, Amsterdam, The Netherlands
,
Tim G. de Meij
4   Department of Pediatric Gastroenterology, VU University Medical Center, Amsterdam, The Netherlands
› Author Affiliations
Further Information

Publication History

05 May 2017

25 July 2017

Publication Date:
11 September 2017 (online)

    Permissions and Reprints

Abstract

Fecal microbiota transplantation (FMT) is a very effective treatment for recurrent Clostridium difficile infection (CDI) in adults. However, there is a paucity of data on FMT in children and associated microbiome changes in this particular group. We describe a child with Down's syndrome and intracranial malignancy, who received FMT for recurrent CDI. Detailed microbiota analysis before and after FMT, and pre- and post-recurrence, linked to microbial communities in the donor feces showed that the patient developed a unique microbiota profile after FMT which was very stable over time despite CDI recurrence and subsequent fidaxomicin therapy. Bacteroidetes were stably acquired from donor feces, while Firmicutes, Actinobacteria, Fusobacteria, Verrucomicrobia, and Proteobacteria were unique to the patient. The diversity of microbiota of the patient increased from a Shannon diversity index of 2.08 pre-FMT to 3.12 post-FMT. Our findings underscore that patients with Down's syndrome may well tolerate and benefit from FMT even in a severely immunocompromised state.

Keywords

fecal microbiota transplantation - Clostridium difficile infection - Down's syndrome - microbiota analysis - child
 

  • References

  • 1 Lo Vecchio A, Zacur GM. Clostridium difficile infection: an update on epidemiology, risk factors, and therapeutic options. Curr Opin Gastroenterol 2012; 28 (01) 1-9
    CrossrefPubMedGoogle Scholar
  • 2 Nicholson MR, Thomsen IP, Slaughter JC, Creech CB, Edwards KM. Novel risk factors for recurrent Clostridium difficile infection in children. J Pediatr Gastroenterol Nutr 2015; 60 (01) 18-22
    CrossrefPubMedGoogle Scholar
  • 3 Morinville V, McDonald J. Clostridium difficile-associated diarrhea in 200 Canadian children. Can J Gastroenterol 2005; 19 (08) 497-501
    CrossrefPubMedGoogle Scholar
  • 4 Hourigan SK, Oliva-Hemker M, Hutfless S. The prevalence of Clostridium difficile infection in pediatric and adult patients with inflammatory bowel disease. Dig Dis Sci 2014; 59 (09) 2222-2227
    CrossrefPubMedGoogle Scholar
  • 5 Kelsen JR, Kim J, Latta D. , et al. Recurrence rate of Clostridium difficile infection in hospitalized pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis 2011; 17 (01) 50-55
    CrossrefPubMedGoogle Scholar
  • 6 Hourigan SK, Oliva-Hemker M. Fecal microbiota transplantation in children: a brief review. Pediatr Res 2016; 80 (01) 2-6
    CrossrefPubMedGoogle Scholar
  • 7 van Nood E, Vrieze A, Nieuwdorp M. , et al. Duodenal infusion of donor feces for recurrent Clostridium difficile . N Engl J Med 2013; 368 (05) 407-415
    CrossrefPubMedGoogle Scholar
  • 8 Cammarota G, Ianiro G, Gasbarrini A. Fecal microbiota transplantation for the treatment of Clostridium difficile infection: a systematic review. J Clin Gastroenterol 2014; 48 (08) 693-702
    CrossrefPubMedGoogle Scholar
  • 9 Surawicz CM, Brandt LJ, Binion DG. , et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 2013; 108 (04) 478-498 , quiz 499
    CrossrefPubMedGoogle Scholar
  • 10 OpenBiome. Available at: http://www.openbiome.org/ . Accessed Month 04, 2017
    PubMed
  • 11 van Beurden YH, de Groot P, Van Nood E, Nieuwdorp M, Keller JJ, Goorhuis A. Complications, effectiveness, and long term follow-up of fecal microbiota transfer by nasoduodenal tube for treatment of recurrent Clostridium difficile infection. United European Gastroenterol J 2017; 5 (06) 868-879
    CrossrefPubMedGoogle Scholar
  • 12 Budding AE, Grasman ME, Lin F. , et al. IS-pro: high-throughput molecular fingerprinting of the intestinal microbiota. FASEB J 2010; 24 (11) 4556-4564
    CrossrefPubMedGoogle Scholar
  • 13 Eck A, de Groot EFJ, de Meij TGJ, Welling M, Savelkoul PHM, Budding AE. Robust microbiota-based diagnostics for inflammatory bowel disease. J Clin Microbiol 2017; 55 (06) 1720-1732
    CrossrefPubMedGoogle Scholar
  • 14 Daniels L, Budding AE, de Korte N. , et al. Fecal microbiome analysis as a diagnostic test for diverticulitis. Eur J Clin Microbiol Infect Dis 2014; 33 (11) 1927-1936
    CrossrefPubMedGoogle Scholar
  • 15 Goldacre MJ, Wotton CJ, Seagroatt V, Yeates D. Cancers and immune related diseases associated with Down's syndrome: a record linkage study. Arch Dis Child 2004; 89 (11) 1014-1017
    CrossrefPubMedGoogle Scholar
  • 16 Cocchi G, Mastrocola M, Capelli M, Bastelli A, Vitali F, Corvaglia L. Immunological patterns in young children with Down syndrome: is there a temporal trend?. Acta Paediatr 2007; 96 (10) 1479-1482
    CrossrefPubMedGoogle Scholar
  • 17 Biagi E, Candela M, Centanni M. , et al. Gut microbiome in Down syndrome. PLoS One 2014; 9 (11) e112023
    CrossrefPubMedGoogle Scholar
  • 18 Russell G, Kaplan J, Ferraro M, Michelow IC. Fecal bacteriotherapy for relapsing Clostridium difficile infection in a child: a proposed treatment protocol. Pediatrics 2010; 126 (01) e239-e242
    CrossrefPubMedGoogle Scholar
  • 19 Kahn SA, Young S, Rubin DT. Colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection in a child. Am J Gastroenterol 2012; 107 (12) 1930-1931
    CrossrefPubMedGoogle Scholar
  • 20 Russell GH, Kaplan JL, Youngster I. , et al. Fecal transplant for recurrent Clostridium difficile infection in children with and without inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2014; 58 (05) 588-592
    CrossrefPubMedGoogle Scholar
  • 21 Pierog A, Mencin A, Reilly NR. Fecal microbiota transplantation in children with recurrent Clostridium difficile infection. Pediatr Infect Dis J 2014; 33 (11) 1198-1200
    CrossrefPubMedGoogle Scholar
  • 22 Kronman MP, Nielson HJ, Adler AL. , et al. Fecal microbiota transplantation via nasogastric tube for recurrent Clostridium difficile infection in pediatric patients. J Pediatr Gastroenterol Nutr 2015; 60 (01) 23-26
    CrossrefPubMedGoogle Scholar
  • 23 Walia R, Garg S, Song Y. , et al. Efficacy of fecal microbiota transplantation in 2 children with recurrent Clostridium difficile infection and its impact on their growth and gut microbiome. J Pediatr Gastroenterol Nutr 2014; 59 (05) 565-570
    CrossrefPubMedGoogle Scholar
  • 24 Hourigan SK, Chen LA, Grigoryan Z. , et al. Microbiome changes associated with sustained eradication of Clostridium difficile after single faecal microbiota transplantation in children with and without inflammatory bowel disease. Aliment Pharmacol Ther 2015; 42 (06) 741-752
    CrossrefPubMedGoogle Scholar
  • 25 Louie T, Cannon K, Denis MS, Byrne B, Ward L. Quantitative real-time PCR measurement of the impact of fidaxomicin or vancomycin treatment of Clostridium difficile infection on the intestinal microbiome, compared with normal controls. Clin Microbiol Infect 2010; 16: S166
    PubMedGoogle Scholar